Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Title: 

EVALUATION OF BCL-2 EXPRESSION IN BREAST CANCER

Type: PAPER
Author(s): ANDALIB ALI REZA*,REZAEI ABAS,SHOKOUHI R.
 
 *IMMUNOLOGY DEPARTMENT - ISFAHAN MEDICAL SCHOOL, ISFAHAN MEDICAL SCIENCE UNIVERSITY (IUMS), ISFAHAN, IRAN
 
Name of Seminar: BIENNIAL CONGRESS ON IMMUNOLOGY, ASTHMA AND ALLERGY
Type of Seminar:  CONGRESS
Sponsor:  IRAN UNIVERSITY OF MEDICAL SCIENCES AND HEALTH SERVICES
Date:  2007Volume 6
 
 
Abstract: 

Background: Over-expression of BCL-2 proto-oncogene has been stated to be involved in solid tumor formation and linked to program cell death pathways. Cell line models indicate that BCL-2 over-expression enhances both tumorigenicite and metastatic potential. To evaluate the BCL-2 protein expression on breast tumor paraffin embedded fixed tissue and sought for association with the BCL-2 protein release in patient serum, the present study was designed.
Methods & Materials: Immunohistochemistry method was applied for breast tumor sections on 35 surgically removed patient samples and 35 normal or benign tissue samples. The serums taken from both patient and control group was tested for soluble BCL-2 (BMs244/3 Kit) using ELISA technique. Tumor stage, grade, size, patient menopause, ages, from patient files were utilized to analysis the association between the parameters assayed.
Results: The analysis shows that 67.6% of the tumor sections were positive for BCL-2 expression and 32.4% negative. The BCL-2 protein expression in normal/benign section tumor was 57.12% positive and 42.85% negative. The BCL-2 serum levels were 3.6+1.07ng/ml in patient group and 3.23+0.06ng/ml in control group. A weak correlation was found between BCL-2 serum levels and tissue expression of the molecules (r=0.382, P=0.049). a negative association (but not statically significance) was obtained between BCL-2 and low grade stages (r=-0.375, P=0.08). A positive and significant correlation was achieved between BCL-2 and menopause with r=0.523, P=0.005, and also between ages and serum BCL=2 with r=0.488, P=0.011.
Conclusion: Although majority of the breast tumor tissue express the BCL-2, the mean BCL-2 serum levels were not significantly difference between the patient control groups. So, the present data would lead us to use the BCL-2 expression in tissue at the level of protein expression or mRNA level, but the using of the serum level would be very limited for clinical propose.

 
Keyword(s): 
 
Yearly Visit 49   tarjomyar
 
Latest on Blog
Enter SID Blog